Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment
- 7 October 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesBlood Cancer Journal, 2013
- Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma CellsClinical Lymphoma Myeloma and Leukemia, 2013
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaBritish Journal of Haematology, 2011
- Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphomaBlood, 2011
- Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trialBritish Journal of Haematology, 2009
- How I treat Waldenström macroglobulinemiaBlood, 2009
- Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenström's MacroglobulinemiaCancer Research, 2009
- CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemiaBlood, 2008
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003